8-K: Wellgistics Launches Brenzavvy for Diabetes Market

Wellgistics Health announces the commercial launch of its diabetes drug Brenzavvy to its 6,500+ pharmacy network, targeting the $16 billion SGLT-2 inhibitor market.

Summary

• Wellgistics Health has commenced the commercial launch of Brenzavvy, a diabetes prescription drug, to its network of 6,500 independent pharmacies.
• The launch targets 33 million Americans diagnosed with type II diabetes, particularly those who are uninsured and underinsured and whose out-of-pocket costs for SGLT-2 drugs exceed Brenzavvy's cash price.
• The SGLT-2 inhibitor market reached sales of $16.8 billion in 2024 and is projected to grow to $28.9 billion by 2033, with the United States representing 40.8% of this market.
• The company's proprietary EinsteinRx artificial intelligence pharmacy platform will alert pharmacists to patients with a likely class 1A recommendation for an SGLT-2 inhibitor, or those who would benefit from Brenzavvy.
• Pharmacists will use EinsteinRx to educate providers on Brenzavvy's benefits and competitive price compared to other SGLT-2 inhibitors like Jardiance.
• This launch establishes a new model for next-generation reformulated drugs, offering patient-specific advantages and reduced out-of-pocket costs.

Sentiment

Score: 8

Explanation: The commercial launch of a new drug into a large and growing market, coupled with a strategic approach to patient access and pharmacist empowerment through AI, presents a strong positive outlook for the company's growth and market position.

Positives

• Commercial launch of Brenzavvy into the significant and growing $16.8 billion SGLT-2 inhibitor market, projected to reach $28.9 billion by 2033.
• Strategic focus on underserved populations, including 33 million type II diabetics, particularly the uninsured and underinsured, by offering a competitively priced alternative.
• Leveraging the proprietary EinsteinRx AI platform to empower pharmacists, optimize prescribing decisions, and improve patient access to medication.
• Creation of new remuneration opportunities for pharmacists through product dispensing and provider education services, enhancing their return on investment.
• Establishes a new market access model for later-generation drugs with product profile advantages, potentially setting a blueprint for future launches.

Risks

• Forward-looking statements involve risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied.
• Certain factors that could cause actual future results to differ materially are noted in connection with such statements, but other unanticipated factors could arise.
• Risks regarding forward-looking statements are discussed in SEC filings, including an extensive discussion in the Registration Statement on Form S-1 declared effective on September 25, 2025.

Future Outlook

The company believes its pharmacist-led provider education model will enable a blueprint for other later-generation drugs with similar product profile advantages to rapidly establish market share. The SGLT-2 inhibitor market is projected to grow significantly, reaching $28.9 billion by 2033.

Management Comments

• "Pharmacists are uniquely positioned to help drive better outcomes for their patients without increasing out-of-pocket costs." Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health.
• "EinsteinRx is empowering these trusted healthcare professionals with the advanced technology they need to get the right drug to the right patient at the right time." Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health.
• "We believe that this pharmacist-led provider education model will enable the blueprint for other later-generation drugs with similar product profile advantages to rapidly establish market share." Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health.

Industry Context

The announcement positions Wellgistics Health to capitalize on the substantial and growing SGLT-2 inhibitor market for type II diabetes, which currently exhibits suboptimal prescription rates (only 11.9% for class 1A recommendations). By targeting uninsured and underinsured patients with a competitively priced drug and leveraging AI-powered pharmacist education, Wellgistics aims to disrupt the market dominated by entrenched leaders like Jardiance, potentially improving patient access and care outcomes, especially in rural communities.

Comparison to Industry Standards

• Brenzavvy is positioned as a competitive alternative to entrenched market leaders such as Jardiance and other SGLT-2 inhibitors.
• The company highlights Brenzavvy's competitive price point, which aims to reduce out-of-pocket costs for patients compared to existing SGLT-2 inhibitors.
• The current guideline-recommended prescription rate for SGLT-2 inhibitors in diabetics with a class 1A recommendation is only 11.9%, indicating a significant gap in optimal care that Wellgistics aims to address through pharmacist-driven education.

Stakeholder Impact

• Shareholders: Potential for increased revenue, market share, and long-term growth due to the launch of a new product in a significant and expanding market.
• Patients (Type II Diabetics): Improved access to SGLT-2 inhibitors, particularly for uninsured and underinsured individuals, with potentially lower out-of-pocket costs and optimized therapy selection.
• Pharmacists: New revenue streams from product dispensing and remuneration opportunities for patient/provider education, enhancing their role in patient care and business ROI.
• Providers: Access to new information and a competitively priced treatment option (Brenzavvy) to help optimize prescribing decisions for their diabetic patients.
• Competitors: Increased competition in the SGLT-2 inhibitor market, potentially impacting pricing strategies and market share for existing drugs like Jardiance.

Next Steps

• Rollout of the EinsteinRx artificial intelligence pharmacy platform into the Wellgistics Pharmacy Network's point-of-sales systems.
• Pharmacists will work to rapidly educate providers on the benefits of Brenzavvy versus other SGLT-2 inhibitors.
• The company anticipates this pharmacist-led provider education model will serve as a blueprint for other later-generation drugs to establish market share.

Key Dates

Recommendation

The commercial launch of Brenzavvy into the substantial and growing SGLT-2 inhibitor market, combined with a strategic focus on underserved patient populations and leveraging proprietary AI for market penetration, presents a strong growth opportunity. The competitive pricing and pharmacist-led education model could enable rapid market share capture, making this a compelling long-term investment for investors seeking exposure to the pharmaceutical and health-tech sectors.

Keywords

Diabetes drug, Brenzavvy, SGLT-2 inhibitor, Wellgistics Health, EinsteinRx, PharmacyChain, Artificial intelligence, Health information technology, Type II diabetes, Prescription drug market, Pharmacist education, Rural communities